Trials / Completed
CompletedNCT03371979
Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Aeglea Biotherapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegzilarginase | Administered IV |
| DRUG | Pembrolizumab | Administered IV |
Timeline
- Start date
- 2017-12-21
- Primary completion
- 2021-01-01
- Completion
- 2021-01-01
- First posted
- 2017-12-13
- Last updated
- 2021-11-04
Locations
22 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03371979. Inclusion in this directory is not an endorsement.